TuberculosisPublished 25 September 2025Country-level heterogeneity in MDR-TB drug susceptibility supports country-specific policy developmentNaomi M. Fuller · Nicholas G. Davies · Timothy D. McHugh · Gwenan M. KnightFrontiers in Tuberculosisdoi 10.3389/ftubr.2025.1667354